Rationale and design of a trial of angiotensin-converting enzyme inhibition in infants with single ventricle

Daphne T. Hsu, Seema Mital, Chitra Ravishankar, Renee Margossian, Jennifer S. Li, Lynn A. Sleeper, Richard V. Williams, Jami C. Levine, Brian W. McCrindle, Andrew M. Atz, Darlene Servedio, Lynn Mahony

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Background: Angiotensin converting enzyme (ACE) inhibitors are known to improve clinical outcome and ventricular function in adults with heart failure. Infants with single-ventricle physiology show abnormalities in ventricular function as well as poor growth. The ability of an ACE inhibitor to preserve ventricular function and improve growth in these infants is unknown. Methods: The Pediatric Heart Network designed a randomized, double-blind trial to compare outcomes in infants with single-ventricle physiology receiving enalapril or placebo. Neonates ≤45 days old were eligible. The primary outcome is weight-for-age Z-score at 14 months of age. Secondary outcomes include other measures of somatic growth, laboratory and functional measures of heart failure, developmental indices, measures of ventricular size and function, and the relationship of the renin-angiotensin-aldosterone system genotype to the response to enalapril. The incidence and spectrum of adverse events will also be compared between treatment groups. Results: A total of 1,245 neonates were screened and 533 (43%) were eligible. The consent rate was 43%; 230 subjects were enrolled. Parental reluctance to participate was the primary reason for non-consent in 79% of the eligible nonconsenting patients. Randomized patients were older, more likely to be male, and more likely to have hypoplastic left heart syndrome than the eligible patients who did not enroll. Conclusions: The results of this randomized trial will make an important contribution to the management of infants with single-ventricle physiology by determining whether initiation of ACE inhibition therapy in the neonatal period improves growth, clinical outcome, and ventricular function.

Original languageEnglish (US)
Pages (from-to)37-45
Number of pages9
JournalAmerican Heart Journal
Volume157
Issue number1
DOIs
StatePublished - Jan 2009
Externally publishedYes

Fingerprint

Ventricular Function
Peptidyl-Dipeptidase A
Enalapril
Growth
Angiotensin-Converting Enzyme Inhibitors
Heart Failure
Newborn Infant
Hypoplastic Left Heart Syndrome
Enzyme Therapy
Renin-Angiotensin System
Genotype
Placebos
Pediatrics
Weights and Measures
Incidence

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Rationale and design of a trial of angiotensin-converting enzyme inhibition in infants with single ventricle. / Hsu, Daphne T.; Mital, Seema; Ravishankar, Chitra; Margossian, Renee; Li, Jennifer S.; Sleeper, Lynn A.; Williams, Richard V.; Levine, Jami C.; McCrindle, Brian W.; Atz, Andrew M.; Servedio, Darlene; Mahony, Lynn.

In: American Heart Journal, Vol. 157, No. 1, 01.2009, p. 37-45.

Research output: Contribution to journalArticle

Hsu, DT, Mital, S, Ravishankar, C, Margossian, R, Li, JS, Sleeper, LA, Williams, RV, Levine, JC, McCrindle, BW, Atz, AM, Servedio, D & Mahony, L 2009, 'Rationale and design of a trial of angiotensin-converting enzyme inhibition in infants with single ventricle', American Heart Journal, vol. 157, no. 1, pp. 37-45. https://doi.org/10.1016/j.ahj.2008.08.030
Hsu, Daphne T. ; Mital, Seema ; Ravishankar, Chitra ; Margossian, Renee ; Li, Jennifer S. ; Sleeper, Lynn A. ; Williams, Richard V. ; Levine, Jami C. ; McCrindle, Brian W. ; Atz, Andrew M. ; Servedio, Darlene ; Mahony, Lynn. / Rationale and design of a trial of angiotensin-converting enzyme inhibition in infants with single ventricle. In: American Heart Journal. 2009 ; Vol. 157, No. 1. pp. 37-45.
@article{a75c5754b597435b951f0a5074cf9770,
title = "Rationale and design of a trial of angiotensin-converting enzyme inhibition in infants with single ventricle",
abstract = "Background: Angiotensin converting enzyme (ACE) inhibitors are known to improve clinical outcome and ventricular function in adults with heart failure. Infants with single-ventricle physiology show abnormalities in ventricular function as well as poor growth. The ability of an ACE inhibitor to preserve ventricular function and improve growth in these infants is unknown. Methods: The Pediatric Heart Network designed a randomized, double-blind trial to compare outcomes in infants with single-ventricle physiology receiving enalapril or placebo. Neonates ≤45 days old were eligible. The primary outcome is weight-for-age Z-score at 14 months of age. Secondary outcomes include other measures of somatic growth, laboratory and functional measures of heart failure, developmental indices, measures of ventricular size and function, and the relationship of the renin-angiotensin-aldosterone system genotype to the response to enalapril. The incidence and spectrum of adverse events will also be compared between treatment groups. Results: A total of 1,245 neonates were screened and 533 (43{\%}) were eligible. The consent rate was 43{\%}; 230 subjects were enrolled. Parental reluctance to participate was the primary reason for non-consent in 79{\%} of the eligible nonconsenting patients. Randomized patients were older, more likely to be male, and more likely to have hypoplastic left heart syndrome than the eligible patients who did not enroll. Conclusions: The results of this randomized trial will make an important contribution to the management of infants with single-ventricle physiology by determining whether initiation of ACE inhibition therapy in the neonatal period improves growth, clinical outcome, and ventricular function.",
author = "Hsu, {Daphne T.} and Seema Mital and Chitra Ravishankar and Renee Margossian and Li, {Jennifer S.} and Sleeper, {Lynn A.} and Williams, {Richard V.} and Levine, {Jami C.} and McCrindle, {Brian W.} and Atz, {Andrew M.} and Darlene Servedio and Lynn Mahony",
year = "2009",
month = "1",
doi = "10.1016/j.ahj.2008.08.030",
language = "English (US)",
volume = "157",
pages = "37--45",
journal = "American Heart Journal",
issn = "0002-8703",
publisher = "Mosby Inc.",
number = "1",

}

TY - JOUR

T1 - Rationale and design of a trial of angiotensin-converting enzyme inhibition in infants with single ventricle

AU - Hsu, Daphne T.

AU - Mital, Seema

AU - Ravishankar, Chitra

AU - Margossian, Renee

AU - Li, Jennifer S.

AU - Sleeper, Lynn A.

AU - Williams, Richard V.

AU - Levine, Jami C.

AU - McCrindle, Brian W.

AU - Atz, Andrew M.

AU - Servedio, Darlene

AU - Mahony, Lynn

PY - 2009/1

Y1 - 2009/1

N2 - Background: Angiotensin converting enzyme (ACE) inhibitors are known to improve clinical outcome and ventricular function in adults with heart failure. Infants with single-ventricle physiology show abnormalities in ventricular function as well as poor growth. The ability of an ACE inhibitor to preserve ventricular function and improve growth in these infants is unknown. Methods: The Pediatric Heart Network designed a randomized, double-blind trial to compare outcomes in infants with single-ventricle physiology receiving enalapril or placebo. Neonates ≤45 days old were eligible. The primary outcome is weight-for-age Z-score at 14 months of age. Secondary outcomes include other measures of somatic growth, laboratory and functional measures of heart failure, developmental indices, measures of ventricular size and function, and the relationship of the renin-angiotensin-aldosterone system genotype to the response to enalapril. The incidence and spectrum of adverse events will also be compared between treatment groups. Results: A total of 1,245 neonates were screened and 533 (43%) were eligible. The consent rate was 43%; 230 subjects were enrolled. Parental reluctance to participate was the primary reason for non-consent in 79% of the eligible nonconsenting patients. Randomized patients were older, more likely to be male, and more likely to have hypoplastic left heart syndrome than the eligible patients who did not enroll. Conclusions: The results of this randomized trial will make an important contribution to the management of infants with single-ventricle physiology by determining whether initiation of ACE inhibition therapy in the neonatal period improves growth, clinical outcome, and ventricular function.

AB - Background: Angiotensin converting enzyme (ACE) inhibitors are known to improve clinical outcome and ventricular function in adults with heart failure. Infants with single-ventricle physiology show abnormalities in ventricular function as well as poor growth. The ability of an ACE inhibitor to preserve ventricular function and improve growth in these infants is unknown. Methods: The Pediatric Heart Network designed a randomized, double-blind trial to compare outcomes in infants with single-ventricle physiology receiving enalapril or placebo. Neonates ≤45 days old were eligible. The primary outcome is weight-for-age Z-score at 14 months of age. Secondary outcomes include other measures of somatic growth, laboratory and functional measures of heart failure, developmental indices, measures of ventricular size and function, and the relationship of the renin-angiotensin-aldosterone system genotype to the response to enalapril. The incidence and spectrum of adverse events will also be compared between treatment groups. Results: A total of 1,245 neonates were screened and 533 (43%) were eligible. The consent rate was 43%; 230 subjects were enrolled. Parental reluctance to participate was the primary reason for non-consent in 79% of the eligible nonconsenting patients. Randomized patients were older, more likely to be male, and more likely to have hypoplastic left heart syndrome than the eligible patients who did not enroll. Conclusions: The results of this randomized trial will make an important contribution to the management of infants with single-ventricle physiology by determining whether initiation of ACE inhibition therapy in the neonatal period improves growth, clinical outcome, and ventricular function.

UR - http://www.scopus.com/inward/record.url?scp=57149106114&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=57149106114&partnerID=8YFLogxK

U2 - 10.1016/j.ahj.2008.08.030

DO - 10.1016/j.ahj.2008.08.030

M3 - Article

VL - 157

SP - 37

EP - 45

JO - American Heart Journal

JF - American Heart Journal

SN - 0002-8703

IS - 1

ER -